Background: Diabetes mellitus (DM) is well recognized to be a major risk factor for coronary artery disease (CAD). Incretin is a gut-derived peptide and one of the enhancers of insulin secretion. Previous studies have reported that a major incretin, glucagon-like peptide-1 (GLP-1), is decreased in patients with DM. GLP-1 analogue is widely used to treat DM in the clinical setting, and is expected to reduce the incidence of CAD. However, there is no evidence regarding the association between blood levels of GLP-1 and coronary plaque characteristics. We sought to assess whether plasma GLP-1 levels are associated with coronary plaque characteristics.
